- Home
- TNYA
as 02-21-2025 4:00pm EST
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 74.7M | IPO Year: | 2021 |
| Target Price: | $17.50 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.86 - $7.01 | Next Earning Date: | 03-17-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Tenaya Therapeutics Inc. News
TNYA Breaking Stock News: Dive into TNYA Ticker-Specific Updates for Smart Investing
GlobeNewswire
19 days ago
Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine
GlobeNewswire
a month ago
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones
MT Newswires
2 months ago
Update: Tenaya Shares Sink After Readout of Heart Disease Therapy Shows Manageable Safety Profile
MT Newswires
2 months ago
Leerink Partners Adjusts Tenaya Therapeutics Price Target to $6 From $8, Maintains Outperform Rating
MT Newswires
2 months ago
Tenaya Says TN-201 Gene Therapy Well Tolerated in Initial Hypertrophic Cardiomyopathy Trial Patients
GlobeNewswire
2 months ago
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
GlobeNewswire
2 months ago
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024
GlobeNewswire
3 months ago
Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Compare TNYA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TNYA Tenaya Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.